Compare 10 GTM agencies for digital health startups by buyer type: provider, payer, pharma and employer. See pricing and fit. Book a free growth audit.
| Company | Best For | Key Strengths | Pricing |
|---|---|---|---|
| QC Growth (QCHC Growth) | Seed to Series A digital health founders needing buyer access and pipeline | Division led by a former RVO Health VP, network-driven access, embedded pod, infrastructure stays with you | $7,500 to $25,000/month, 6 to 12 month engagements |
| Akros Advisory | Companies whose revenue depends on a health plan contract | Only published payer-contracting methodology reviewed here | Not published |
| Accretive Edge | Non-US companies entering the US, or founder-led pipeline needing structure | Provider and payer coverage, fractional commercial leadership | Not published |
| Health Launchpad | Series A healthtech needing demand generation that survives a buying committee | Covers provider, payer and life sciences; ex-healthtech CMOs | Not published |
| memoryBlue | Health IT, device and healthcare security companies with an IT buyer | Most named healthtech clients of any outbound firm here | Not published |
| Informed Consulting | Companies selling through employers, brokers and benefits platforms | The employer channel, which almost nobody else covers | Not published |
| Summit Health Advisors | Network and marketplace models selling into health systems | Advises health systems on vendor selection, so knows the buyer’s process | Not published |
| Health Advances | Products whose commercial blocker is reimbursement | Deepest market access and reimbursement capability reviewed here | Not published |
| Blue Matter Consulting | Regulated products entering the US, especially pharma-partnered | Buyer archetype mapping across all four channels; FDA fluency | Not published |
| Belkins | Clinic-level or self-serve healthcare buyers needing volume | Most documented healthcare case studies of any outbound agency | Not published, tiers by appointment volume |
A GTM agency for digital health startups, also sold as a healthcare go-to-market agency, builds and runs the commercial motion for a company selling into healthcare. In practice the label covers four separate disciplines, and the firms that do one rarely do another.
Commercialization strategy answers who buys, through which channel, at what price, and what has to be true before the first contract. Market access and reimbursement answers whether anyone will pay for it at all, which for a regulated product often determines the business model. Demand generation and marketing builds awareness and credibility with a buying committee. Sales development and execution gets specific people at specific organizations into a conversation and holds a 12-month process together.
The reason the category looks confusing is that these four are sold under the same words. Research for this article found no firm that credibly covers health-system procurement navigation and outbound execution together, and no firm at all that publishes a rate for healthcare commercialization work.
The organizing fact is the buyer. A company selling to hospital systems, one selling to a national payer, one selling through pharma and one selling through employer benefits are in four different businesses, and the right partner changes completely between them.
Healthcare punishes the standard startup playbook harder than any other vertical. Julie Yoo of Andreessen Horowitz sets out five distinct go-to-market motions in The New Go-to-Market Playbooks for Digital Health Startups, from bottom-up B2C2B through risk-based contracting to distribution partnerships, and the firm’s founder’s playbook on channel partnerships in healthcare covers the aggregator route in detail. The channel decision, rather than the product, is usually what determines whether a digital health company reaches scale.
Four problems show up at Seed and Series A:
The cycle outlasts the runway. Provider and payer sales commonly run 9 to 18 months from first conversation to signature, through clinical review, security assessment, legal and finance. A company with 15 months of cash cannot afford to learn this by experiencing it. Capital is also concentrating: Rock Health reports $14.2B raised across 482 US digital health deals in 2025, a 35% year-over-year rise driven by fewer, larger rounds, with 26 nine-figure raises against 18 the year before. Fewer companies are being funded to make the mistake twice.
Generic outbound damages credibility. Healthcare buying is reputation-driven and the relevant communities are small. A clumsy sequence sent to 2,000 hospital executives fails and closes doors that a warm introduction would have opened.
The wrong channel invalidates the model. A product priced for a per-member-per-month payer contract does not work sold to individual clinics, and a product that needs a reimbursement code cannot be sold on operational value alone. Choosing the channel late means repricing and often rebuilding.
A healthcare sales mis-hire is existential. A VP of Sales with a provider network is the wrong person for payer contracting, and the salary at that level plus the time to find out costs most Seed companies two quarters and a meaningful share of their runway. QC Growth’s own hiring math puts a full senior in-house go-to-market team at $57,000 to $81,000 a month once salary and equity are counted, broken down role by role in our in-house GTM team versus fractional cost math.
What good commercialization work produces is not more meetings. It is the right channel chosen deliberately, the right stakeholders reached through routes they respect, and a process that survives the eleven months between interest and signature.
A physician or nurse founder with a product that works in a pilot faces a buying committee that includes a clinical champion, IT, security, compliance, finance and often a value analysis committee. The champion is enthusiastic and cannot sign.
This group needs someone who has navigated that committee before and can keep a multi-stakeholder process moving for a year. Enthusiasm from clinicians is the easiest part to generate and the least predictive of revenue.
A company whose model requires a health plan contract is in a different business from one selling software to a clinic. Payer buying involves actuarial review, pilot design, outcomes evidence and a procurement cycle that does not accelerate for anybody.
What this group needs is payer-specific commercialization help, and the number of firms that do it is small. Provider selling does not transfer.
Selling through self-funded employers, benefits brokers and benefits platforms is a distinct channel with its own gatekeepers and its own annual rhythm tied to open enrollment.
It is also the least-served channel in this category. Of the ten firms reviewed here, two cover it properly, which is worth knowing before starting a search.
For a prescription digital therapeutic, software as a medical device or an imaging AI product, the commercial question is often whether a payment pathway exists rather than whether buyers want it.
This group needs market access and reimbursement expertise before it needs a sales motion, and that capability sits with life-sciences consultancies rather than with go-to-market agencies.
A digital health company with traction in the United Kingdom, the Nordics or Israel entering the US market has to rebuild almost everything: the buyer, the pricing logic, the regulatory position and the reference customers.
What works here is fractional commercial leadership with a US healthcare background rather than a marketing retainer, since the first task is deciding which US channel to attack.
QC Growth is an embedded go-to-market firm for Seed to Series A B2B companies, and its healthcare work runs through a dedicated division, QCHC Growth. The division exists precisely because a motion built for software buyers does not survive contact with providers and payers.
The division is led by Kori Bivens, formerly a VP at RVO Health, with more than ten years in healthcare and work across more than 40 healthcare clients. The services, set out on our digital health practice page, cover go-to-market operations, commercialization, strategic advisory and operator placement, structured as discovery and strategy before contract, then implementation over one to two weeks, then an operate-and-iterate phase. Our six-month healthtech retrospective covers what we learned building it, and the Steadywell case study shows the advisory-council route in practice.
The model is a fractional pod inside the client’s own environment rather than an advisory retainer: a senior operator, a GTM lead, a GTM engineer and BDR support who run the motion day to day.
Healthcare is run by healthcare operators here, not by a generalist team with a healthcare page. Of the ten firms reviewed, eight deliver strategy or marketing and stop short of execution. QCHC Growth does both, which is the gap the research behind this article found nobody else filling.
Access comes through routes healthcare buyers respect. Advisory councils of senior hospital executives, physician networks and conference-driven signal intelligence put the company in front of the right stakeholder with context, rather than arriving cold in an inbox. Our playbook for running events that build pipeline covers the conference half of that, which healthcare companies overspend on and under-convert.
We also treat healthcare as several markets rather than one. Provider, payer, pharma and employer economics each get their own strategy, because a single motion applied across all four is how companies burn two quarters finding out the channel was wrong.
At the end of the engagement, the infrastructure, the data and the playbooks belong to the client, and the division is open to performance-based arrangements where the commercial model supports it.
QC Growth packages run $7,500 to $25,000 per month depending on scope, over 6 to 12 month engagements, with no equity component. The healthcare division is open to performance-based structures where the commercial model supports it.
For the comparison that matters, our own hiring math puts the senior in-house equivalent at $57,000 to $81,000 a month plus 1.25% to 2.75% equity. The full-service GTM engagement page sets out what sits inside that band.
QCHC Growth is the strongest option here for a Seed to Series A digital health founder whose problem is access and execution rather than analysis. The combination of a healthcare-operator-led division, network-based buyer access and an embedded team that actually runs the motion is what the rest of this list splits across two or three vendors. Companies whose blocker is a reimbursement pathway should talk to the market access specialists further down first.
Akros Advisory is a payer go-to-market consultancy for healthtech, focused on proving payer product-market fit and landing Medicare, Medicaid and commercial plan contracts. The entire firm is built around that one channel.
Its products are packaged rather than open-ended: a payer readiness assessment, a go-to-market playbook and a business development program. Its founders state in-house roles at large US insurers, and it also advises health plans themselves, which gives it a view from both sides of the table.
Named client work includes OptionsMD and Dieta, with founder testimonials from both.
Akros is one of the strongest options available for payer commercialization specifically, and the only firm reviewed here with a published payer-contracting methodology. Payer selling is different enough from provider selling that general healthcare background does not substitute for it.
Covering employer, third-party administrator and PACE channels alongside payers is also useful, since those often become the realistic first contract while payer processes run.
Akros Advisory does not publish pricing. Engagements are advisory and scoped directly, with additional course-based material available separately.
Akros Advisory is the right first call for a digital health company whose business depends on a payer contract, and the payer focus is real rather than a vertical page. It is not a fit for provider-focused companies, and the model stops at strategy, so pipeline and execution will need a second partner.
Accretive Edge offers US market entry, sales enablement and commercialization for health technology companies, including fractional commercial leadership. The service lines are narrow and healthcare-only.
Its founder, Andy Strunk, states go-to-market leadership roles at Google Health, UpToDate and Salesforce Health Cloud. The firm covers provider and payer buyers.
Its case studies are anonymized, describing outcomes such as a digital health startup tripling enterprise sales in twelve months without naming the company. Companies named on the site appear in testimonials rather than as client engagements.
Accretive Edge is one of the smartest options for a company that needs senior commercial leadership part-time rather than a marketing program. The US market entry focus is also useful, since that transition is where most non-US digital health companies lose a year.
Its stated background across Google Health, UpToDate and Salesforce Health Cloud covers both the provider and the enterprise health software side.
Accretive Edge does not publish pricing. Engagements are scoped directly.
Accretive Edge suits a digital health company that needs a senior commercial leader shaping the motion part-time, particularly one entering the US from abroad. The absence of named clients and the apparent single-principal structure both warrant extra diligence, and a company needing outreach capacity will need to add it elsewhere.
Health Launchpad is a healthtech marketing agency that helps companies sell into health systems, payers and life sciences organizations. It claims more than 40 healthtech clients over five years, with former healthtech CMOs on a team of around nine.
Named work includes InterSystems, with additional clients including Cobalt Benefits Group, PT Solutions, Nordic and Prompted, plus a testimonial from the Chief Growth Officer of Bluestream Health.
It co-hosts a healthtech marketing podcast with HIMSS and runs a healthtech marketing community, which gives it unusual visibility into the category.
Health Launchpad covers all three major healthcare buyer types, which is rare, and its healthcare account-based marketing capability is real rather than adapted from B2B software practice.
It also publishes the most substantive existing roundup of healthtech marketing agencies, which makes it a useful source on its own category even though it appears in its own list.
Health Launchpad does not publish pricing. Engagements are scoped through consultation.
Health Launchpad is a strong choice for a healthtech company that already has a sales motion and needs demand generation and positioning that holds up in front of a health system buying committee. It will not produce pipeline on its own, and a Seed-stage company whose problem is buyer access rather than awareness is buying the wrong half.
memoryBlue is an outsourced sales development firm with fourteen named verticals, of which health technology is among the more substantive. Its healthcare page claims more than 1,800 sales-accepted leads and describes reps trained on HIPAA and security review, targeting clinical and compliance stakeholders.
Its named healthcare client work includes Homecare Homebase, Asimily, Molecular Devices, Bluesight, Cynerio, Clearwater Compliance and Health Loop, with a wider logo wall including Zocdoc, DrFirst, Inovalon, Suki, DeepScribe and Boston Scientific.
The strength of that evidence sits in health IT infrastructure and healthcare security rather than in clinical or payer selling.
memoryBlue has more named healthcare clients with stated pipeline outcomes than any other outbound firm reviewed here. Its reps reach CISO, CIO and compliance buyers, which is exactly the group that stalls health system security reviews.
Its recruit-to-hire path also gives a practical route to building an in-house team from a working engagement.
memoryBlue does not publish pricing. It offers sales-development-as-a-service and pay-per-meeting models scoped through consultation.
memoryBlue is a good fit for a health IT, device or healthcare security company with an IT buyer and a target account list. For a clinical product selling into a value analysis committee, or anything payer-facing, the model and the evidence both point elsewhere. Logo-wall names should be weighted less heavily than the described case studies.
Informed Consulting is a go-to-market consultancy for digital health and benefits technology startups and their investors. Its single-vertical focus is on the employer and benefits channel, which almost nobody else in this category covers properly.
The firm includes hands-on sales execution support alongside strategy, which is unusual among the advisory firms here. Its named client work centers on Nayya Health, where the site states the company raised substantial Series A and B funding after the engagement, though causation is the firm’s own framing.
One practical note for readers: the firm’s pricing section is placeholder text, which suggests a small operation.
Informed Consulting covers the employer and benefits channel, which is the least-served route in this category and often the fastest first contract for a digital health company. Combining strategy with execution support is also rare among advisory firms.
Working with venture firms on portfolio readiness gives it a useful view of what investors expect commercially.
Informed Consulting does not publish pricing. The pricing section of its site contains placeholder text rather than figures, and engagements are scoped directly.
Informed Consulting is worth a conversation for a digital health company whose route to market runs through employers and brokers, a channel where the alternatives are few. The thin public track record and small size mean it suits a focused channel project rather than a company’s whole commercial program.
Summit Health Advisors is a strategy consultancy for digital health companies, investors and health systems, with particular emphasis on network and marketplace business models. Its three service lines are segmented by client type.
That third client type matters. The firm advises health systems on innovation and vendor evaluation, which means it sees how your buyer actually runs a selection process. It also means it sits on both sides of the table, which is worth raising directly.
Named client work includes Panda Health, with a testimonial from its President and COO.
Summit Health Advisors advises health systems on vendor selection, which gives it unusually direct insight into how digital health purchases get approved or killed. For a company repeatedly losing late-stage deals, that perspective is hard to buy elsewhere.
Its depth on network and marketplace models is also relevant for companies whose value depends on both sides of a marketplace.
Summit Health Advisors does not publish pricing. Engagements are consulting projects scoped directly.
Summit Health Advisors is a smart purchase for a digital health company with a network or marketplace model, or one that keeps losing deals at the evaluation stage and does not know why. It is not a commercial execution partner, and the dual-sided client base is a question to raise in the first conversation rather than after signing.
Health Advances is a commercialization strategy consultancy spanning biopharma, diagnostics, medical technology and digital health. Its go-to-market work includes pricing, reimbursement and market access, which is the hardest part of healthcare commercialization and the part most agencies avoid.
The firm is healthcare-only, which gives it deep domain knowledge. All of its case studies are anonymized, however, so no client can be checked.
Its orientation is pre-commercial pharmaceutical and medical technology launches rather than Seed-stage software, which is the main consideration for readers here.
Health Advances has reimbursement and market access depth that no agency on this list can match. For a product that needs a payment pathway to exist before it can be sold, that capability determines whether there is a business at all.
Its launch roadmaps include profit and loss modeling, which is a different level of rigor from a go-to-market plan.
Health Advances does not publish pricing. Engagements are consulting projects scoped directly.
Health Advances is the right firm when the question is whether a payment pathway exists, which for regulated digital health is frequently the only question that matters. It is the wrong firm for a Seed-stage company that needs pipeline, both on scope and on cost, and the absence of named clients limits what can be diligenced.
Blue Matter Consulting is a life sciences strategy consultancy with a digital health team and a published model for US market entry. Its stated depth covers prescription digital therapeutics and AI medical imaging.
Its functional range includes market access, medical affairs, real-world evidence and policy, which reflects pharmaceutical consulting roots rather than startup go-to-market.
The firm names no clients on the pages reviewed, and digital health is one practice within a larger life sciences business.
Blue Matter is the only firm reviewed that maps buyer archetypes across private practice, health system, insurer, employer and pharmaceutical channels in a single published model. For a company still unsure which channel to attack, that is a useful starting structure.
Its pharmaceutical channel expertise is also real, which matters for companies whose route to market runs through a pharma partner.
Blue Matter Consulting does not publish pricing. Engagements are consulting projects scoped directly.
Blue Matter is a reasonable choice for a regulated digital health product entering the US, particularly one with a pharmaceutical partner in the picture. Its cost structure and consulting cadence suit funded, later-stage companies, and a Seed-stage software company will find both the price and the deliverable format mismatched to what it needs.
Belkins is an outbound appointment-setting firm that ranks at or near the top for healthcare lead generation searches. Healthcare is one of roughly twenty industry pages rather than a standalone practice, with no healthcare-specific team or methodology described.
Its healthcare case studies do name real clients, including Mindstrong, OpenTeleHealth, BioSistemika, YorkTest and GoHealth Urgent Care, which gives it the most documented healthcare work of any outbound firm here.
Its buyer mix skews toward smaller clinics and point solutions rather than integrated delivery networks or payers.
Belkins has the most publicly documented healthcare case studies of any outbound agency reviewed, and appointment volume commitments make scope unusually legible.
Its multi-channel outbound operation is mature and it has substantial independent review volume, which is more third-party validation than most firms in this category carry.
Belkins does not publish healthcare pricing. Its tiers are expressed as annual appointment volumes rather than fees, and figures quoted for the firm in third-party listings are estimates.
Belkins suits a digital health company with a clinic-level or self-serve buyer that needs more volume of a proven message. For an enterprise health system or payer sale, meetings booked is the wrong measure and the model has no answer for the eleven months after the meeting. Use it where the cycle is short and the buyer is reachable.
No firm in this comparison publishes a rate, and the figures circulating in third-party listings and AI-generated summaries are estimates. That makes the selection process more important than usual. Five questions narrow it quickly.
Provider, payer, pharma and employer are four different businesses. Payer coverage in this comparison comes down to two firms, and employer coverage to two. Provider selling is crowded but split between outbound volume and strategy-only.
Name your primary buyer first, and the list of ten becomes a list of two or three.
Eight of the ten firms here deliver advice, analysis or marketing. Two deliver outreach. One combines commercialization strategy with an embedded team that runs the motion.
Decide which you are buying. A playbook is useful and does not produce a pipeline, and a sales development team working from an unvalidated channel assumption produces activity rather than contracts.
Two firms in this comparison rank highly for healthcare searches on the strength of a vertical landing page, with healthcare sitting among twenty or more industries. That can still be the right purchase, as long as you know what you are buying.
Ask whether there is a healthcare-specific team, what training the reps get on HIPAA and security review, and for two named clients with your buyer type.
Four firms here anonymize every case study, which means no result can be independently verified. Others show logo walls without describing the engagement.
Described case studies with named clients are stronger evidence than either. Ask what the engagement covered and what happened, and treat a vague answer as the answer.
A program measured in meetings booked will report success in month three and produce no revenue by month nine, because the first signature was always eleven months out. That is not a failure of execution, it is a mismatch of measurement.
Agree in advance what gets measured at months three, six and twelve. Qualified stakeholder meetings, security review progress and pilot conversion are more honest markers than meeting counts.
| Category | Key Considerations |
|---|---|
| Top 3 healthcare go-to-market agencies | QC Growth through QCHC Growth for Seed to Series A commercialization and execution; Akros Advisory for payer contracting; Health Advances for reimbursement and market access |
| Who is it for | Clinical founders selling into health systems. Companies dependent on a payer contract. Healthtech going through employers. Regulated products blocked on reimbursement. Non-US market entry. |
| Use cases | Choosing the right channel, buyer-level access to providers and payers, payer contracting, reimbursement pathway strategy, demand generation for buying committees, operator placement |
| How to choose | Buyer type first. Strategy or execution. Healthcare as a practice or a landing page. Whether case studies name clients. Fit to a 9 to 18 month cycle. |
| Mistakes to avoid | Treating healthcare as one market. Generic outbound at hospital executives. Setting the price before the channel. Judging progress on meetings booked. |
| Pricing starts | No firm reviewed publishes a healthcare rate. QC Growth publishes $7,500 to $25,000 a month. Other figures in circulation are third-party estimates. |
| Firm | Top strengths | Main limitations |
|---|---|---|
| QC Growth (QCHC Growth) | Healthcare-operator-led division; strategy and execution together; network-driven access | Not a market access consultancy; no pharma-channel specialism |
| Akros Advisory | Only published payer-contracting method; packaged products; sees both sides | No provider or pharma coverage; small team; advisory only |
| Accretive Edge | Healthcare-only service lines; fractional commercial leadership; US entry focus | Single principal; no named clients; no outreach capacity |
| Health Launchpad | Covers provider, payer and life sciences; real healthcare ABM | Marketing not sales; clients skew large; no pricing |
| memoryBlue | Named healthcare clients with pipeline figures; reaches IT and security buyers | Health IT only; no payer framing; junior rep model |
| Informed Consulting | Employer and benefits channel coverage; includes execution support | One named client; no payer depth; unfinished website |
| Summit Health Advisors | Advises health systems on vendor selection; network model depth | Strategy only; dual-sided client base; stage unstated |
| Health Advances | Deepest reimbursement and market access capability; financial modeling | Built for pharma and medtech launches; anonymized case studies |
| Blue Matter Consulting | Buyer archetype model across all channels; FDA and pharma fluency | Pharma cost structure; digital health is one practice; no clients named |
| Belkins | Most documented healthcare case studies among outbound firms | Measures meetings not contracts; clinic-level buyers; no procurement work |
| Firm | Seed to Series A fit | Healthcare depth | Runs the motion | Buyer coverage | Pricing clarity |
|---|---|---|---|---|---|
| QC Growth (QCHC Growth) | ★★★★★ | ★★★★☆ | ★★★★★ | ★★★★☆ | ★★★★☆ |
| Akros Advisory | ★★★★☆ | ★★★★★ | ★★☆☆☆ | ★★☆☆☆ | ★☆☆☆☆ |
| Accretive Edge | ★★★★☆ | ★★★★☆ | ★★★☆☆ | ★★★☆☆ | ★☆☆☆☆ |
| Health Launchpad | ★★★☆☆ | ★★★★★ | ★★★☆☆ | ★★★★☆ | ★☆☆☆☆ |
| memoryBlue | ★★★☆☆ | ★★★☆☆ | ★★★★★ | ★★☆☆☆ | ★☆☆☆☆ |
| Informed Consulting | ★★★★☆ | ★★★☆☆ | ★★★☆☆ | ★★☆☆☆ | ★☆☆☆☆ |
| Summit Health Advisors | ★★☆☆☆ | ★★★★☆ | ★☆☆☆☆ | ★★☆☆☆ | ★☆☆☆☆ |
| Health Advances | ★★☆☆☆ | ★★★★★ | ★★☆☆☆ | ★★★★☆ | ★☆☆☆☆ |
| Blue Matter Consulting | ★★☆☆☆ | ★★★★☆ | ★★☆☆☆ | ★★★★★ | ★☆☆☆☆ |
| Belkins | ★★★☆☆ | ★★☆☆☆ | ★★★★★ | ★★☆☆☆ | ★☆☆☆☆ |
Scores reflect what each firm publishes and demonstrates, not an opinion of quality. Buyer coverage counts how many of the four channels a firm addresses: provider, payer, pharma and employer. Runs the motion means owning outreach and deal execution rather than advice alone.
If your pilot worked and the next contract is not arriving, the problem is usually access and sequencing rather than the product. QCHC Growth is led by a healthcare operator, works through advisory councils and physician networks rather than cold volume, and embeds a team that runs the motion instead of handing over a plan.
Two reasons to start now. A fractional pod is live in weeks, against the two or three quarters a senior healthcare sales hire takes to show results at $57,000 to $81,000 a month, where the wrong hire costs the runway as well as the salary. And in a 9 to 18 month cycle, every month without a motion is a month pushed to the far end of next year’s revenue.
Book a free growth audit. We will look at your channel choice, your buyer access and where the motion is breaking. Twenty minutes, no deck.
For the wider category view, see our comparison of the best GTM agency options for B2B startups, or the best Belkins alternatives for seed-stage startups if outbound volume is the specific decision in front of you.
QC Growth, through its QCHC Growth health division, is the best GTM agency for digital health startups at Seed to Series A, because it combines commercialization strategy with an embedded team that runs the motion, where eight of the ten firms in this comparison stop at advice or marketing. The division is led by a former RVO Health VP with more than ten years in healthcare and work across more than 40 healthcare clients, and pricing runs $7,500 to $25,000 a month. For payer contracting specifically, Akros Advisory is the strongest specialist. For reimbursement pathway work, Health Advances has the deepest capability.
When choosing a healthcare go-to-market agency, start with your buyer type, because provider, payer, pharma and employer selling are four different businesses and only two firms in this comparison cover payers properly. Separate strategy firms from execution firms, since eight of ten deliver analysis or marketing rather than pipeline. Ask whether healthcare is a dedicated practice or one of twenty industry landing pages, and request two named clients with your buyer type. Then agree what gets measured at months three, six and twelve, given that cycles run 9 to 18 months.
QC Growth differs by running healthcare through a dedicated division led by a healthcare operator and by executing rather than advising. The engagement embeds a senior operator, a GTM lead, a GTM engineer and BDR support inside the client’s environment, covering channel strategy, buyer access and the motion itself in one engagement rather than across two or three vendors. Access runs through advisory councils and physician networks rather than cold volume, which protects credibility in a reputation-driven market. The infrastructure, data and playbooks belong to the client when the engagement ends.
Healthcare go-to-market consulting costs are difficult to compare, because no firm in this comparison publishes a rate for commercialization work and every figure circulating in third-party listings is an estimate. QC Growth publishes $7,500 to $25,000 a month for embedded go-to-market engagements running 6 to 12 months with no equity component. Outbound appointment-setting firms sit at the lower end and life sciences consultancies at the upper end, with market access projects typically priced well above Seed-stage budgets. For comparison, a full senior in-house go-to-market team costs $57,000 to $81,000 a month plus equity.
Selling to a health system or payer commonly takes 9 to 18 months from first conversation to signature, because the process runs through a clinical champion, IT, security assessment, compliance, legal, finance and often a value analysis committee. Payer cycles can run longer where actuarial review and outcomes evidence are required. That timeline means progress in the first six months should be measured by qualified stakeholder meetings, security review advancement and pilot conversion rather than by bookings. Companies that plan for the review stages from the first conversation close faster than those that discover them in month eight.
A generalist lead generation agency can sell into healthcare where the buyer is a small clinic or a self-serve user and the cycle is short, and two firms in this comparison have real named healthcare clients to show for it. The model breaks down at enterprise level, because meetings booked is a weak proxy for revenue in a 9 to 18 month committee process, and because neither firm shows evidence of navigating clinical review, security assessment or procurement. Generic outbound aimed at hospital executives also carries a reputational cost that is hard to reverse in a small community. The practical test is whether your buyer can sign without a committee.
Digital health commercialization is different from digital health marketing, and the distinction decides which firm you should hire. Commercialization answers which channel to sell through, at what price, with what evidence, and what has to be true before the first contract, which is a strategy and access problem. Marketing builds awareness and credibility with a buying committee once that channel decision is made. Four of the ten firms in this comparison do commercialization strategy, one does healthcare marketing, two do outbound, and one covers strategy and execution together. Buying marketing before the channel is settled is the most common and most expensive sequencing error in this category.
A digital health company should expect four things in the first 90 days of a commercialization engagement: a channel decision backed by reasoning, a named target account list with the right stakeholder identified inside each one, a route to those stakeholders that does not rely on cold volume, and a reporting view built around stage progression. Signed contracts inside 90 days are unrealistic against a 9 to 18 month cycle. Ask for those deliverables in writing before signing. A firm that answers only in meetings booked has not understood the cycle it is selling into.
Kori Bivens leads QCHC Growth, the health division of QC Growth, where she works with Seed to Series A digital health founders on commercialization into providers, payers and employers. She was previously a VP at RVO Health and has more than ten years in healthcare, with work spanning more than 40 healthcare clients across go-to-market operations, commercialization and operator placement.